[Scleroderma].
Sclerodermas may occur in two basic forms: localized sleroderma (LSc) and systemic scleroderma (SSc). Pseudoscleroderma as well as overlap syndromes have to be differentiated from these two variants. From the clinical point of view, localized scleroderma can be subdivided into type I = plaque-like LSc (= morphea), type II = linear LSc, and type III = deep LSc. According to the degree of the cutaneous involvement, systemic scleroderma can likewise be classified into type I = sclerodactylia, type II = acrosclerosis, and type III = scleroderma with primary involvement of the trunk (diffuse scleroderma). In LSc, we never find systemic involvement; SSc, in contrast, is almost always associated with Raynaud's phenomenon, changes of the esophagus, as well as an increased titer of antinuclear antibodies (Hep-2 cell test). Only 23% of our patients with LSc showed elevated ANA titers. We present and discuss data of 56 patients with LSc and 52 patients with SSc. Evidence in the literature as well as our own findings suggest that the pathogenesis of LSc is different from that of SSc. The influence of various mediators and cytokines on the collagen metabolism might be regarded as a theoretical approach in order to develop new therapeutic regimens. This is even more important since there is still no efficient mode of treatment for neither localized nor systemic scleroderma.
Hautklinik, Universität Düsseldorf.
K
K
Scharffetter
P
P
Kind
D
D
Wollny-Protzel
H C
HC
Schuppe
H J
HJ
Lakomek
G
G
Goerz
D000974:Antibodies, Antinuclear / Q000032:analysis; D000907:Antibodies, Bacterial / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis; D001898:Borrelia / Q000276:immunology; D003238:Connective Tissue / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D012594:Scleroderma, Localized / Q000209:etiology* / Q000276:immunology; D012595:Scleroderma, Systemic / Q000209:etiology* / Q000276:immunology
D000974:Antibodies, Antinuclear; D000907:Antibodies, Bacterial; D001323:Autoantibodies
Die Sklerodermien.